Fumaric acid esters in children with psoriasis ongoing study

[Fred]

This is an ongoing study from Germany looking at Fumaric acid esters in children with psoriasis.

Quote:

---

Background:
Given that there is no standard systemic treatment for children and adolescents with plaque psoriasis, this non-interventional, multicenter, retrospective study collected data on the efficacy and safety of long-term treatment with fumaric acid esters (FAEs) in this particular patient group.

Patients and methods:
In patients younger than 18 years of age at the start of FAE treatment, data on efficacy and safety was retrospectively collected for at least 36 months.

Results:
Data from 127 patients (aged 6–17 years) was collected for treatment durations of up to 60 months. Physician's Global Assessment, Psoriasis Area and Severity Index, and Body Surface Area showed marked improvement in the first six months. After 36 months, these parameters had, on average, improved by up to two-thirds of baseline values. Thirty-seven patients experienced at least one adverse event (AE), which was FAE-related in 36 individuals. Three AEs (proteinuria (one case), flushing (two cases)) persisted during the observation period while on treatment. Fifteen AEs led to the discontinuation of therapy; nearly all of these cases were related to gastrointestinal disorders.

Conclusions:
The KIDS FUTURE study – for the first time – included a larger population of children and adolescents with psoriasis who were treated with FAEs. The data obtained suggests that long-term FAE therapy in this patient group may be effective and safe. The results are currently being verified in an ongoing clinical study.

Source: onlinelibrary.wiley.com

Author Information:
Dermatologikum Hamburg, Germany
Dermatology/Allergology Practice, Eltville, Germany
Department of Dermatology, Venereology, and Allergology of the Ruhr University, Bochum, Germany
SCIderm GmbH Hamburg, Germany